GtoPdb Ligand ID: 9411

Synonyms: CA028_0496 | CDP4940 | gL7gH9 | UCB-4940 | UCB4940 | Zu-G1
Compound class: Antibody
Comment: Bimekizumab (UCB4940) is a rat-derived humanized Phase 2 monoclonal antibody targeting both IL-17A and IL-7F (dual antagonist), with potential for controlling autoimmune conditions mediated by these proinflammatory cytokines. Safety, pharmacokinetics and clinical efficacy of bimekizumab in mild psoriasis are reported in [2]. Claimed in patent WO2008047134 as CA028_0496 [1].
Compound class Antibody
International Nonproprietary Names
INN number INN
9878 bimekizumab
CA028_0496 | CDP4940 | gL7gH9 | UCB-4940 | UCB4940 | Zu-G1
Database Links
Specialist databases
IMGT/mAb-DB 486
Other databases
GtoPdb PubChem SID 328083513
Search PubMed clinical trials bimekizumab
Search PubMed titles bimekizumab
Search PubMed titles/abstracts bimekizumab